false 0001534525 0001534525 2023-12-06 2023-12-06 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2023-12-06 2023-12-06 0001534525 XBIO:PurchaseWarrantsMember 2023-12-06 2023-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

 

FORM 8-K

________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 6, 2023

________________________

 

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in charter)

 

Nevada   001-37937   45-2952962
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

945 Concord Street  
Framingham, Massachusetts 01701
(Address of principal executive offices) (Zip Code)

 

(781) 778-7720

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   XBIO   The Nasdaq Stock Market
Purchase Warrants   XBIOW   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On December 6, 2023, Xenetic Biosciences, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on the following three proposals and cast their votes as described below.

 

  1. The Company’s stockholders approved the election of the following nine nominees with each director receiving votes as follows:

 

Name   For   Withheld   Broker Non-Votes
Dr. Grigory Borisenko   447,811   26,571   356,015
Dr. James Callaway   431,833   42,549   356,015
Mr. Firdaus Jal Dastoor   446,807   27,575   356,015
Mr. Jeffrey Eisenberg   255,632   218,750   356,015
Dr. Dmitry Genkin   461,413   12,969   356,015
Dr. Roger Kornberg   431,824   42,558   356,015
Mr. Adam Logal   447,840   26,542   356,015
Mr. Moshe Mizrahy   460,534   13,848   356,015
Mr. Alexey Vinogradov   447,886   26,496   356,015

 

  2. The Company’s stockholders voted upon and approved the ratification of the selection of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. The votes on this proposal were as follows:

 

For   Against   Abstained   Broker Non-Votes
804,522   21,792   4,083   –

 

  3. The Company’s stockholders voted upon, on a non-binding, advisory basis, the Company’s named executive officer compensation. The proposal did not receive an affirmative vote of a majority of the shares cast. The votes on this proposal were as follows:

 

For   Against   Abstained   Broker Non-Votes
153,605   318,665   2,112   356,015

 

No other matters were considered or voted upon at the Annual Meeting.

 

 

 

 

 

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  XENETIC BIOSCIENCES, INC.
   
  By: /s/ James Parslow                                        
Date: December 8, 2023 Name:   James Parslow
  Title:     Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
v3.23.3
Cover
Dec. 06, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 06, 2023
Entity File Number 001-37937
Entity Registrant Name Xenetic Biosciences, Inc.
Entity Central Index Key 0001534525
Entity Tax Identification Number 45-2952962
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 945 Concord Street
Entity Address, City or Town Framingham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01701
City Area Code (781)
Local Phone Number 778-7720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, $0.001 par value per share  
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol XBIO
Security Exchange Name NASDAQ
Purchase Warrants  
Title of 12(b) Security Purchase Warrants
Trading Symbol XBIOW
Security Exchange Name NASDAQ
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Xenetic Biosciences Charts.
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Xenetic Biosciences Charts.